Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ETBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and ...
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation ...
Power Metals entered into a cesium concentrate offtake agreement with Albemarle Corporation, a US$16 billion global critical ...
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the ...
Quincey to Continue as Executive Chairman of the BoardATLANTA--(BUSINESS WIRE)--The Coca-Cola Company today announced that ...
Solutions Market Overview:The global electronic clinical outcome assessment (eCOA) solutions market is expected to grow at a ...
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement ...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...
Antin Infrastructure Partners (Paris:ANTIN) has agreed to acquire NorthC Datacenters, a leading enterprise colocation data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback